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Aim. To study the prevalence of cognitive and emotional impairment following a minor ischemic stroke compared to an age-
matched group with non-ST-elevation myocardial infarction (NSTEMI). Methods. We included patients aged 18-70 years with a
minor ischemic stroke defined as modified Rankin Scale (mRS) 0-2 at day 7 or at discharge if before and age-matched NSTEMI
patients with the same functional mRS. We applied a selection of cognitive tests and the patients completed a questionnaire
comprising of Hospital Anxiety and Depression scale (HADS) and Fatigue Severity Scale (FSS) at follow-up 12 months after the
vascular event. Results of cognitive tests were also compared to normative data. Results. 325 ischemic stroke and 144 NSTEMI
patients were included.Therewas no significant difference in cognitive functioning between ischemic stroke andNSTEMI patients.
Minor stroke patients and to a lesser extentNSTEMIpatients scoredworse onmore complex cognitive functions including planning
and implementation of activities compared to validated normative data. For the minor stroke patients the location of the ischemic
lesion had no influence on the result. The prevalence of anxiety, depression, and fatigue was significantly higher in the stroke
group compared to the NSTEMI group. Depression was independently associated with reduced cognitive function. Discussion
and Conclusion. Minor ischemic stroke patients, and to lesser degree NSTEMI patients, had reduced cognitive function compared
to normative data, especially executive functioning, on 12-month follow-up. The difference in cognitive function between stroke
and NSTEMI patients was not significant. Depression was associated with low scores on cognitive tests highlighting the need to
adequately address emotional sequelae when considering treatment options for cognitive disabilities.
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1. Introduction
Acute ischemic stroke is a heterogeneous clinical syndrome
and can lead to a variety of physical and cognitive clinical
manifestations. Sensorimotor deficits are usually fairly evi-
dent, whereas cognitive deficits may be rather inconspicuous.
However, a recent review [1] reported that poststroke demen-
tia might affect as many as 30% of stroke patients. Fatigue has
been reported in 34.7% of patients following a minor stroke
[2].
Patients with minor strokes are thought to have good
long-term prognosis. Sensorimotor symptoms are often
marginal at admission and improve quickly the first days and
weeks. Most patients are discharged directly to their homes
and may have no physical neurological deficits at follow-up
after fewweeks. However, they may have cognitive symptoms
compatible with a mild cognitive impairment or dementia
[3–8] and suffer from fatigue [2, 9] and emotional symptoms
[3, 10] of longer duration. Anxiety following a minor stroke
is less explored [3, 11], whereas subsequent depression and
fatigue after minor strokes are better known [2, 3, 10]. These
symptoms may have substantial impact on daily functions,
rehabilitation, and the patients’ ability to stay in employment
after an ischemic stroke [3, 12, 13].
High prevalence of cognitive impairment and depression
after TIA and minor stroke are discussed in a systematic
review from 2014 [3], but only a few of the included studies
were of high quality. The studies revealed large variations
in methodology and distribution of included cases [3]. The
authors concluded that the knowledge of poststroke anxiety
was limited. The prevalence of fatigue was high, but the
studies were few and lacked relevant comparison groups. A
prospective study from Turkey found significant cognitive
impairment in patients with minor stroke and transient
ischemic attack compared to controls [5], and, in a prospec-
tive Swiss study, poststroke fatigue was found in 34.7% at 12
months after a minor stroke [2].
Assessment of cognitive dysfunction and emotional
symptoms is not routinely performed during follow-up and
knowledge of the long-term impact of cognitive and emo-
tional symptoms is sparse [3, 5], but attention to this issue is
growing [13, 14]. There is no consensus on diagnostic criteria
for minor stroke [15–19] which hampers research on this
topic. There is consequently a need for studies investigating
the consequences of cognitive and emotional impairment of
minor strokes. The aim of this study was to assess the preva-
lence of cognitive and emotional impairment, in patients
with minor ischemic stroke. Non-ST-Elevation myocardial
infarction (NSTEMI) patients were selected as a control-
group because both conditions implicate symptomatic vas-
cular disease and related risk factors with the intracerebral
lesion as the difference. Comparison with normative data was
included for the cognitive tests.
2. Material and Methods
A 12-month follow-up was performed with a selection of
cognitive tests and a questionnaire on anxiety, depression,
and fatigue. The presence of anxiety and/or depression
is defined as emotional impairment. A control group of
NSTEMI patients was chosen.
Emotional symptoms in our study is defined as anxiety
and depressive symptoms and fatigue.
Patients were as follows: ischemic stroke was defined in
accordance to the Baltimore-Washington Cooperative Young
Stroke Study Criteria [20] comprising neurological deficits
lasting more than 24 hours because of ischemic lesions
or transient ischemic attacks where CT or MRI showed
infarctions related to the clinical findings. Inclusion criteria
were as follows: ischemic stroke patients 18-70 years with
minor ischemic stroke defined as mRS 0-2 [21] at day 7 or at
discharge if before and TIA-patients with an ischemic lesion
verified at MRI. NSTEMI patients aged 18-70 years with mRS
0-2.
Exclusion criteria were as follows: patients with a major
stroke defined as mRS > 2 day 7 or at discharge if before
and patients with deterioration in mRS to more than 2 in
the observational period of any cause. NSTEMI patients with
mRS > 2 of any cause.
Recruitment was as follows; ischemic stroke patients were
recruited consecutively from stroke units at Molde Hospi-
tal, Haukeland University Hospital, and St Olav’s Hospital.
Patients from other participating stroke units, Department of
Neurology at St Olavs Hospital, Kristiansund Hospital, Volda
Hospital, and Aalesund Hospital, were included whenever
practical, but not always consecutively. Recruitment period
was 01/01/13-12/31/16. NSTEMI patients were recruited from
Haukeland University Hospital, Ålesund Hospital, Molde
Hospital, and Kristiansund Hospital in the same time.
Baseline investigation was as follows: ischemic stroke
patients underwent routine examination with NIHSS [22],
traditional risk factors including hypertension, diabetes mel-
litus, hypercholesterolemia, smoking, BMI ≥ 25, and brain
imagingwithCT and/orMRI. Patientswere treated according
to Norwegian guidelines for ischemic stroke. Most patients
with mRS ≤ 2 after 7 days or at discharge had no need for
further rehabilitation and were discharged to their home.
Demographic data were collected from the initial admis-
sion time for the ischemic stroke and NSTEMI.
3. Assessment of Cognitive
and Emotional Function
Clock drawing test [23] were used as screening of global
cognitive function. Clock drawing test assesses visuospatial
function [23]. Trail-making tests A and B, Color-Word
interference test, and Verbal fluency (FAS) were used to test
executive function [24].The Color-Word interference test is
divided into 4 items: color naming, color reading, inhibition
and inhibition/switching, testing mental flexibility, mental
speed, and inhibition. These tests were drawn from the
Delis–KaplanExecutive Function System (D-KEFS).D-KEFS
was developed to provide reliable normative data for a range
of executive functions [25].
Memory was tested with the CERAD ten-words learning
task [26]. CERAD (Consortium to Establish a Registry for
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Table 1: Characteristics of patients and controls at baseline (time for event).
Ischemic stroke n 324 (%) NSTEMI n 144 (%) p value
Age (mean) 58.0 (10.0∗) 60.3 (6.6∗) .009
Females 120 (37) 31 (22) .001
Education (1,2,3)a
51 (16) 20 (14)
.07148 (46) 68 (47)
121 (37) 56 (39)
Employed before event 217 (67) 111 (77) .03
Risk factors
Hypertension 174 (54) 68 (47) .2
Diabetes mellitus 39 (12) 22 (15) .3
Atrial fibrillation 46 (14) 15 (10) .3
Hypercholesterolemiab 151 (47) 80 (56) .07
Smokingc 114 (35) 65 (45) .04
BMI mean 26.7 (4.4∗) 27.4 (3.7∗) .06
Overweight (BMI≥25) 189 (58) 98 (68) <.001
a1≤ 10 years of education, 2 10-13 years of education,≥ 14 years of education, bhypercholesterolemia is defined as treatmentwith cholesterol loweringmedication,
and csmoking is defined as current smoker or smoking within the last 12 months. ∗SD.
Alzheimer’s Disease) is standardized validated test battery
for the assessment of Alzheimer disease [26] with normative
data adjusted for age and education [27]. Minor stroke and
NSTEMI patients were compared with validated normative
data for Trail-making test A and B, Color-Word interference
test, Verbal fluency, and Ten-word learning task [26, 28].
Scores falling below 1.5 SDof themeanwere characterized
as abnormal.
Ischemic stroke patients were screened by the Ullevål
aphasia screening test [29].
3.1. Questionnaires. Hospital Anxiety and Depression scale
(HADS) was used to assess anxiety and depression [30]. A
score ≥ 8 on the anxiety (HADS-A) or depression (HADS-
D) items indicates possible presence of anxiety or depression
disorders [30]; a total score ≥ 15 indicates amixture of anxiety
and depression.
Fatigue Severity scale (FSS) was used to assess fatigue [31].
FSS is a nine-item questionnaire that assesses the effect of
fatigue on daily living. Each item is a statement on fatigue
that the subject rates from 1, “completely disagree”, to 7,
“completely agree”. [32] Fatigue is defined as FSS score ≥ 5
[32].
Cognitive testing was performed by trained research
nurses or by the neurologist responsible for the study.
Written informed consent was obtained from the patients
for their anonymized information to be published in this
article.
The ethics committee of Rogaland, Hordaland, and Sogn
and Fjordane (REC west) approved this study (REC no.
2012/1708).
4. Statistics
Student’s t-test was used to assess differences in mean
values. Chi square was used to assess differences in categoric
variables. Multivariable linear regressions were used to assess
association between more than two variables. The level og
significans was set to p=.05. All significance testing was done
as two-tailed tests.
STATA 14 (Statacorp 4905 Lakeway Drive, College Sta-
tion, Texas 77845 USA) was used for analyses.
5. Results
In total, 324 ischemic stroke patients were included at admis-
sion and followed up at 3 months, and 288 were followed
up at 12 months. Either a phone call or a letter recruited
the NSTEMI group after their vascular event. 144 of 146
NSTEMI patients who accepted participation completed the
questionnaire and cognitive tests. Table 1 shows baseline
demographic data on ischemic stroke and NSTEMI patients.
The mean age for ischemic stroke patients was significantly
lower than for the NSTEMI group, 58 years (SD = 10.0) and
60 years (SD = 6.6), respectively. Proportion of women was
significantly higher in the ischemic stroke group. There were
significantly more NSTEMI patients who smoked compared
to the ischemic stroke patients (p =.04). More NSTEMI
patients than ischemic stroke patients were employed (p
=.03).Themean value for premorbid mRS in ischemic stroke
patients was 0.3 (SD = 0.6), mRS at discharge/day 7 was 1.2
(SD= 0.8), and NIHSS at discharge/day 7 was 0.8 (SD = 1.0).
The number of patients treated with antidepressant was 24
(8%) and in the control group 10 (7%).
5.1. Cognitive Function. Table 2 shows results of the cognitive
tests, HADS, and FSS in ischemic stroke and NSTEMI
patients. Cognitive tests were compared with each other and
normative data for both groups.
Clock-drawing test score was 5 in both groups, indicating
no deficit in either group on this test.
There were no differences between ischemic stroke and
NSTEMI patients in Ten-word learning task, Trail-making
tests A or B, Verbal fluency, or Color-Word Interference tests
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Table 2: Chi square test to compare cognitive testsHAD and FSS amongminor ischemic strokes andNSTEMI patients. Proportion of patients






10-words learning taska 17(6) 9(6) 1.0
10-words learning task,
delayed recallab 27(10) 12(8) .7
Trail-making Ac 15(5) 4(3) .2
Trail-making Bc 39(14)∗ 16(11) .4
Verbal fluencyc 32(11) 17(12) .8
Color-Word Interference
tests
Color namingc 59(20)∗ 20(14) .09
Color readingc 52(18)∗ 17(12) .07
Color inhibitionc 58(20)∗ 20(14)∗ .1∗
Color inhibition/switchingc 58(20)∗ 17(12) .03
Error scores
Naming errorsd 16(6) 5(3) .8
Reading errorsd 29(10) 17(12) .6
Inhibition errorsc 18(6) 6(4) .4
Inhibition/switching
errorscc 25(9) 8(6) .1
Proportion with ≥2
abnormal cognitive tests 220(77) 122(84) .05
Questionnaire
HADS e 45(16) 0(0) <.001
HADS-Af 52(19)∗ 19(13) .2
HADS-D f 34(9)∗ 9 (6) .06
FSS (n=279/142) g 81(29) 22(15) .002
aAdjusted for age and educational level, btested with 5 minutes delay, cscaled score, and dcumulative percentage. 5Anxiety and/or depression was defined as
HADS ≥ 15, fanxiety was defined as HADS-A≥8, and fdepression was defined as HADS-D≥8. Fatigue defined as FSS ≥ 5. hp value between ischemic stroke
and NSTEMI ∗P value ≤0.05 compared with normative data.
except for the subtest Inhibition/Switching (p =.03) where the
stroke group scored worse.
Ischemic stroke patients scored worse than normative
data for Trail making test B (p =.02), Color naming (p
<.001), Color reading (p =.001), Inhibition (p <.001), and
Inhibition/Switching (p =.000). NSTEMI patients scored
worse than normative data in the subtest Color naming (p
=.02) and Inhibition/Switching (p =.02).
The percentage of subjects with ≥2 abnormal cognitive
tests was 77% in the ischemic stroke patients, and 84% in the
NSTEMI patients (p=.05).
There was a significant gender difference in the color-
word inhibition test in the patient group where males soored
worse (p=.05), but no significant gender difference in the
control group (table available on request).
Table 3 shows that performance on most tests (memory,
mental flexibility, mental speed, and inhibition and executive
functions) was independently associated with education and
depression and, to a lower degree, with age, gender, and
fatigue. Stratifying age groups did not change this (table
available on request). We performed the same analyses in the
stroke and NSTEMI patients separately and found that the
association between age and cognitive impairment became
significant in one more test (5 of 13 cognitive tests), wheras
the result for the NSTEMI group was unchanged. There was
an association between diabetes mellitus and color inhibition
and between overweight and inhibition error (table ii in
suppmelentary data).
There were significant differences as a function of later-
ality in Verbal fluency and the inhibition part of the Color-
Word inhibition test, with higher prevalence of deficient
scores if infarctions were located in the left versus right
hemisphere (Table 4). There were no significant differences
in cognitive impairment, anxiety, depression, and fatigue
between subcortical and cortical infarctions (Table 4).
The mean value of the aphasia score at 12 months in the
ischemic stroke patients was 51.7 (SD = 1.1) of a total of 52
points.
Fatigue was as follows: the prevalence of fatigue was
higher in the ischemic stroke than NSTEMI patients (29%
versus 15%, p =.002).
5.2. Anxiety and Depression. There was a difference in the
prevalence of combined anxiety and depression measured
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Table 3: Linear regression analyses with cognitive tests as dependent variables showing beta values for all independent variables (beta).
Age Males Ischemic stroke vs NSTEMI Higher education Marital stage HAD-A HAD-D FSS
10-words learning taska -.17∗ -.18∗ .19∗ .15∗ -.04 -.08 -.03 -.06
10-words learning task- delayedab -.20∗ -.17∗ .04 .13∗ -.05 -.07 -.03 -.13
Trail-making Ac -.04 -.002 -.04 .26∗ -.09 .08 -.09 .02
Trail-making Bc -.04 -.08 -.03 .33∗ -.04 -.03 -.13∗ -.02
Verbal fluencyc -.09∗ -.10∗ .01 .30∗ -.01 .01 -.08 -.10
Color-word interference tests
Color namingc .01 -.12 -.06 .19∗ -.06 .03 -.19 -.08
Color readingc .08 -.003 -.07 .24∗ -.02 .12 -.15∗ -.10
Color inhibitionc -.02 -.10∗ -.08 .27∗ -.002 .02 -.09 -.13∗
Color inhibition/switchingc -.02 -.09∗ -.06 .24∗ .01 .03 -.09 -.15∗
Error scores
Naming errorsd -.11∗ -.02 -.04 .03 .06 -.02 -.17∗ .06
Reading errorsd -.04 -.11 .04 -.04 .14 .07 .06 -.10
Inhibition errorsc -.09 .06 -.06 -.01 -.04 .06 -.13 -.05
Inhibition/switching errorsc .06 -.06 -.07 .16∗ .01 .03 .00 -.13∗
aNot adjusted for age and educational level in a linear model, btested with 5 minutes delay, cscaled score adjusted for age, and dcumulative adjusted for age
percentage. Significant difference with normative data is labeled with ∗.







p Left side n=94 (%)
Right side
n= 85 (%) p
10-word learning taska 10 (9.4) 3 (3.1) .07 7 (7.5) 4 (4.6) .4
10-word learning task
delayedab 10 (9.4) 6 (6.3) .4 7 (7.6) 7 (8.2) .9
Trail-making Ac 6 (5.6) 5 (5.2) .9 5 (5.3) 6 (6.9) .7
Trail-making Bc 19 (17.6) 12 (12.4) .3 17 (18.1) 8 (9.2) .08
Verbal fluencyc 15 (13.9) 15 (15.5) .8 17 (18.1) 7 (8.1) .05
Color-Word Interference
tests
Color namingc 23 (21.3) 21 (21.7) 1.0 18 (19.2) 14 (16.1) .6
Color readingc 24 (22.4) 15 (15.5) .2 21 (22.3) 11 (12.6) .09
Color inhibitionc 16 (14.8) 15 (15.6) .9 21 (22.3) 5 (5.6) .001
Color inhibition/switchingc 24 (22.2) 22 (22.3) .9 21 (22.3) 15 (17.2) .4
Error scores
Naming errorsd 6 (5.6) 6 (6.2) .8 8 (8.5) 5 (5.6) .5
Reading errorsd 9 (8.3) 10 (10.3) .6 8 (8.5) 10 (11.5) .5
Inhibition errorsc 8 (7.4) 4 (4.2) .3 11 (11.8) 5 (5.8) .2
Inhibition/switching
errorsc 6 (5.6) 10 (10.4) .2 8 (8.6) 9 (10.3) .7
No of abnormal cogn tets 40 (38.8) 32 (33.3) .4 36 (39.6) 24 (28.2) .1
Questionnaires
HADSe 23 (22.6) 11 (12.1) .06 18 (19.8) 11 (13.4) .3
HADS-A f 25 (24.3) 15 (16.1) .2 22 (23.9) 12 (14.5) .1
HADS-D f 13 (12.4) 12 (12.9) .9 11 (12.0) 11 (12.9) .8
Fatigue severity scale (FSS)
g 32 (30.2) 24 (25.5) .5 26 (27.7) 23 (28.1) 1.0
aAdjusted for age and educational level, btested with 5 minutes delay, cscaled score, and dcumulative percentage.eAnxiety and/or depression was defined as
HADS ≥ 15, fanxiety was defined as HADS-A≥8, and fdepression was defined as HADS-D≥8. Fatigue was defined as FSS ≥ 5.
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by total HADS score between ischemic stroke and NSTEMI
patients, with a significantly larger proportion of stroke
patients (16%) scoring above the cutoff thanNSTEMIpatients
(0%) (p =.00). However, there were no significant differences
in the symptoms of either anxiety (p =.2) or depression (p
=.06).
6. Discussion
6.1. Cognitive Function. The differences between patients
with ischemic stroke and NSTEMI were not statistically
significant on most tests, even though the ischemic stroke
patients scored numerically worse on all cognitive tests
except verbal fluency and reading errors. This trend may
suggest that the ischemic stroke patients have slightly more
encompassing cognitive problems than NSTEMI patients do.
However, given that ischemic stroke patients have demon-
strated brain lesions, it is surprising that the difference on
cognitive function between the two groups is so slight. One
explanation may be the low NIHSS. We only found a modest
association between the risk factors diabetes and overweigt,
and impairment of the cognitive tests as shown in table ii in
supplemental material. Cerebrovascular risk factors are asso-
ciated with development of cerebrovascular changes, which
increases with increasing age. An age-dependent association
between smoking and white matter hyperintensities is found
[33]. Our patients population is relatively young, something
which may explain the lack of association between cognitive
impairment and risk factors. It is known that cerebrovascular
risk factors also increases the risk of Alzheimer’s disease
[34] and our findings may reflect a preclinical stage of this
neurodegenerative disease. NSTEMI patients may also have
vascular changes in the brain; this is unknown because no
brain imaging was done in the NSTEMI group.
The NSTEMI group scored significantly worse on some
cognitive tests compared to the normative data (Table 2),
which suggests that NSTEMI patients also have a cere-
brovascular disease. This finding is consistent with a prior
study that found that cognitive outcomes after a coronary
syndrome were similar to minor stroke [35]. Both ischemic
stroke and NSTEMI patients may have prior cerebrovascular
lesions, but our study has no data on this. We therefore
do not know if prior cerebrovascular lesions can explain
this lack of difference. Furthermore, many NSTEMI patients
are treated with a coronary intervention, which can cause
silent infarctions in the brain, even though a recent study
did not find significant cognitive impairment after coronary
angiography and percutaneous coronary intervention [36,
37]. However, NSTEMI patients in our study are signifi-
cantly older compared to the minor stroke patients which
increases the risk of neurodegenerative diseases such as early
Alzheimer’s disease.
The proportion with more than two abnormal cognitive
testswas 77% in ischemic stroke patients and 84% inNSTEMI
patients. This suggests that both patient groups are associated
with a generalized cognitive dysfunction. It also highlights
that there are important cognitive sequelae following vascular
disease for the majority of the patients regardless of where the
disease manifests itself.
Patients with ischemic stroke showed significant deficits
in several cognitive domains compared to normative data.
Areas of dysfunction include mental flexibility, mental speed,
and inhibition.These higher order cognitive functions under-
pin executive functioning, which encompass supervisory
skills that are crucial to successful and purposeful goal-
directed behavior [38].These functions are important in plan-
ning and implementation of activities. Impaired executive
dysfunction can have detrimental effect on social function
and the ability to stay in work.
Increasing age showed significant correlation with lower
scores on several cognitive tests, as expected because cere-
brovascular changes increase with increasing age. The slight
difference in the results of the cognitive tests in the stroke and
NSTEMI group is hardly clinical significant. Males showed
significantly lower scores on several cognitive tests than
females at the same age, despite no difference in educational
level, which can possibly be explained by higher load of
vascular disease in males [39]. This effect was clearer in the
NSTEMI patients.
Employmentwasmore frequent amongNSTEMIpatients
than among ischemic stroke patients even though NSTEMI
patients were older. A possible explanation is that some
ischemic stroke patients may have had cognitive disabilities
prior to the index stroke because of chronic cerebrovascular
disease. Perhaps a more insidious onset of cognitive difficul-
ties in the NSTEMI patients permits a gradual accommoda-
tion to their vocation despite cognitive difficulties.
The location of the ischemic lesion only influenced two of
13 cognitive tests and did not seem to be a strong determining
factor for cognitive function. However, both tests were verbal
and were more affected by left hemisphere lesions, which is in
the direction expected given that language normally is located
in the left hemisphere.
6.2. Fatigue. We found a high prevalence of fatigue among
the ischemic stroke patients, which is consistent with prior
studies [2, 3, 9, 40–42].The prevalence in other studies varies
between 23 and 40%, compared to 29% in our study. The
prevalence in the NSTEMI-group was low compared to the
study of Eckhardt et al. [43]. Younger NSTEMI patients and
fewer patients with cardiac failure in our study may partly
explain these discrepancies.
6.3. Anxiety and Depression. The prevalence of combined
anxiety and depression (HADS>15) was significantly higher
in the ischemic stroke patients than NSTEMI patients, but
the difference in pure anxiety or depression symptoms was
not significant. The scores were compared to the prevalence
of anxiety and depression in the population-based study
of HUNT (The Nord-Trondelag Health study) [44] where
about 9% of the population reported elevated anxiety and
5% elevated depression (on HADS). There were significantly
more anxiety and depression disorders in the ischemic stroke
group than in the study of HUNT. However, this was not the
case for the NSTEMI group.
As expected, reported depression was associated with
lower scores on some cognitive tests. Cognitive dysfunction
among patients with reported depression is a common
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finding [45]. Reported anxietywas not associatedwith change
in cognitive performance. This finding is in contrast to prior
studies investigating a stroke population [46] and in healthy
individuals [47]. Both of these studies found that anxiety had
a detrimental impact on cognitive functions. Anxiety and
depression disorders are treatable and may hamper recovery
if untreated. Depression is in itself found to be associated
with worsening and enduring cognitive dysfunction even
after remission [48].The current findings of a broad cognitive
dysfunction in both patient groups suggest that theymay have
less cognitive reserves and may therefore be extra vulnerable
to events of adverse effects on cognitive function including
depression.
Strengths and weaknesses are as follows: strength of this
study is the large number of patients and inclusion of controls.
It is amulticenter study and reflects the patients in the middle
and western part of Norway. The existence of normative data
made it possible to detect a significant difference for both
patients and controls compared to the normative data.
There are some weaknesses. Recruitment of individuals
to the control group was difficult which may have biased
selection. Different study nurses and one neurologist per-
formed testing. Some patients live far from the hospital. A
long traveling distance may have influenced the ability to
concentrate in performing cognitive tests. Lack of registration
of proportion of percutaneous coronary intervention (PCI) in
the NSTEMI-group is another limitation, because PCI may
cause ischemic lesions in the brain as shown in a study from
2016 [36, 37].
7. Conclusion
We found no significant difference in cognitive function
between minor ischemic stroke patients and NSTEMI
patients. However, the stroke patients and to a lesser degree
NSTEMI patients had reduced cognitive function compared
to normative data, especially executive function, on long term
follow-up. Prevalence of cognitive impairment increasedwith
increasing age. Presence of risk factors and gender seemed
not to substantially influence cognitive function. Depression
was independently associated with low scores on cognitive
tests, suggesting that treatments targeting depression can be
a valuable approach to improve cognitive disabilities in these
patients. The prevalence of anxiety, depression, and fatigue
was significantly higher in the stroke group compared to the
NSTEMI group.
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